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Letters to the EditorTACE treatment in hepatocellular carcinoma: What should
we do now?To the Editor:
We read with much interest the comment by Forner et al. [1] on
the recently published Cochrane review on Transcatheter Arterial
(Chemo) Embolization (TACE/TAE) treatment in hepatocellular
carcinoma by Oliveri et al. [2]. The debate on the effectiveness
of TACE in patients with intermediate stage hepatocellular carci-
noma (HCC) is still open, indeed. On the one hand, as summarized
in the updated American Association for the Study of Liver Dis-
eases (AASLD) guidelines, there is no doubt that the level of evi-
dence on the efﬁcacy of TACE in the treatment of intermediate
stage HCC is strong (IA, according to the standard evaluation
[3], with a consequently strong grade of recommendation [Grade
A]). On the other hand, there is also no doubt that this strength
lies basically on the results of two randomized prospective stud-
ies [4,5] that deeply condition the two meta-analyses published
on the topic [6,7]. Nevertheless, TACE is also supported by the
fact that it is used in the everyday clinical practice of every center
involved in the management of HCC, a very low level (IV), but still
important, evidence.
Dr. Forner correctly underlines that one of the papers quoted in
Olivieri’s meta-analysis, the Doffoel’s randomized prospective
trial of TACE vs. tamoxifen [8], presents many biases and includes
patients that may have been ‘‘sub-optimally staged, selected and/
or treated’’. In several French studies, indeed (see also the two
Pelletier’s articles [9,10]), the survival after TACE is so short that
being affected by an intermediate stage HCC in France at the
end of the last century would have suggested to move to other
countries for treatment. Indeed, the reported 1-year survival
(ranging from 25% to 50%) was not considered acceptable else-
where and in past years those two studies heavily conditioned
the clinical evaluation of TACE as a treatment for patients with
multinodular HCC.
The Cochrane review in any case casts new doubts on the
topic, doubts that induce to wonder what to do in patients with
intermediate stage HCC, if one accepts the conclusions of the
review. In our experience, based on the data (prospectively col-
lected over 20 years) of the ITA.LI.CA database, patients with
intermediate stage HCC treated by TACE present a median sur-
vival of 35 months (42 months in those treated in the last dec-
ade), with 1- and 5-year survivals of 80% and 18%, respectively.
Having said this, it is worth noting that only a fraction of patients
with an intermediate stage HCC were treated by TACE, while in
the other cases, the treatment options vary from surgery or per-
cutaneous treatments to best supportive care, depending on a
number of factors not considered in the Barcelona Clinic Liver
Cancer (BCLC) algorithm, such as age, co-morbidities, patient’s
decision, and local expertise, particularly, as far as the availability
of highly experienced surgical teams is concerned. Interestingly
enough, patients with intermediate stage HCC who can be treated
more aggressively tend to survive longer than those treated byJournal of Hepatology 2TACE (median survival of 52 months and 5-year survival over
30%). Our, still unpublished, data clearly demonstrate that TACE
should not be abandoned, remaining the standard of care, in clin-
ical practice, for most patients with intermediate stage HCC.
However, the indication to TACE should not be automatic and,
if the patients are considered eligible for more aggressive treat-
ments, in a multidisciplinary approach also including percutane-
ous ablation and surgery, an even better survival can be obtained.
Nowadays, there is indication for a combined/sequential tailored
treatment, with a strategy that involves hepatologists, interven-
tional radiologists, and surgeons. Likely, in the near future an
adjuvant treatment with sorafenib or new anti-angiogenetic mol-
ecules will be part of this strategy.
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1. The upper part shows the results of the SHARP-trial, the lower part
ws the results of the APT. The bars are showing the median time from study
y to symptomatic progression (light blue) and, further on, to median overall
ival (dark blue).To the Editor:
A recent review published in the Journal of Hepatology discusses
the opportunities for chemotherapy in hepatocellular carcinoma
(HCC) [1]. In this review, the authors conclude that ‘‘Sorafenib is
currently regarded as the standard of care in selected patients with
advanced HCC based on two large randomised placebo controlled
trials’’ [2,3]. Furthermore, the introduction suggests its use as a
palliative therapeutic. But what actually deﬁnes a palliative treat-
ment? A decent deﬁnition of palliative chemotherapy is given by
V.R. Archer in 1999: ‘‘Palliative chemotherapy is deﬁned as treat-
ment in circumstances where the impact of intervention is insufﬁ-
cient to result in major survival advantage, but does affect
improvement in terms of tumor-related symptoms, and where the
palliation/toxicity trade-off from treatment clearly favors symptom
relief’’ [4].
Assuming sorafenib to be a palliative treatment, the data of
the SHARP [2] and the Asian Paciﬁc Trial (APT) [3] can be used
to extrapolate the medians of asymptomatic and symptomatic
time of survival. In both studies, the eligibility criteria included
an Eastern Cooperative Oncology Group (ECOG) performance
status score of 2 or less (i.e. ranging from full active: 0, to
capable of self-care but unable to work: 2) [5]. It thus seems
ﬁne to assume that the patients entered the study with a pre-
served quality of life. Furthermore, both studies give data for
the cut-off, where an asymptomatic patient changes to a symp-
tomatic one: the time to symptomatic progression (TTSP). Both
studies deﬁned symptomatic progression (SP) as death, a
decline to an ECOG performance status score of 4 (i.e. com-
pletely disabled, conﬁned to bed, and chair) [5] or an increase
of 4 points in the Hepatobiliary Symptom Index (FISH-8) ques-
tionnaire [6]. Last but not least, both studies also report overall
survival.
The SHARP trial reported a median overall survival (OS) of
10.9 months vs. 7.9 months for sorafenib vs. placebo respectively
(p <0.001), and a median time to symptomatic progression of
4.1 months vs. 4.9 months (p = 0.77) [2]. The APT reported a med-
ian OS of 6.5 months vs. 4.2 months for sorafenib vs. placebo
(p = 0.14), and a median TTSP of 3.5 months vs. 3.4 (p = 0.50)
[3]. Assuming that patients were asymptomatic at the beginning
of the study, the majority of patients remained asymptomatic
until the median of TTSP was reached. Beyond this, the majority
of patients was symptomatic and stayed so until the median of
overall survival was reached (Fig. 1).While sorafenib deﬁnitely marks a milestone in the treatment
f non-resectable HCC, both trials only show a prolongation of
urvival with minimal to no impact on the time to symptomatic
rogression (in both trials, this outcome was non-signiﬁcant).
ven thought sorafenib may not reﬂect the characteristics of an
deal ‘‘palliative drug’’, a patient’s wish for treatment in the set-
ing of non-curable disease should never be underestimated.
or example, in 104 women with breast cancer who already
ad three cycles of cyclophosphamide, methotrexate, and 5-ﬂuo-
ouracil (CMF) as adjuvant treatment, the patients were asked to
ate the survival beneﬁt that would justify 6 months of such a
reatment. Surprisingly, 50% of all patients would participate in
nother 6 months of treatment for a small 1% gain in 5 year-sur-
ival [7].
Thus, the prescribing doctor and his or her patients should
e aware that while sorafenib may prolong the median survival
f 2–3 months [2,3], the symptoms associated with the disease
r its treatment remain untouched. For patients in whom the
ain desire is for a treatment ‘‘to buy them some time’’, sorafe-
ib remains a good option. However, the patient must then be
ware of all the possible adverse events, the possible longer
ymptomatic course, and the substantial costs of the treatment
nvolved (about 2400 EUR per month). In the end, treatment
eferral also remains a valid choice and accepting the natural
ourse of a disease may indeed be the best option for someol. 57 j 221–232
